The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery

Inclusion Criteria: * Male and Female aged between 18 and 75 years are eligible; * It was confirmed by histopathology that it was a mucosal melanoma; * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1; * Complete excision of primary focal area, surgical incision; All patients must have disease-free status documented by a complete physical examination and imaging studies prior to registration; * No adjuvant therapy was received; * No treatment contraindication, peripheral blood, normal liver, kidney function and electrocardiogram are normal; WBC≥4.0×10\^9/L,PLT≥100×10\^9/L,Hgb≥90g/L; serum urea nitrogen, cr≤ULN; ALT,AST,TBI≤1.5\*ULN, * Males or female of childbearing potential must: agree to use using a reliable form of contraception (eg, oral contraceptives, intrauterine device, control sex desire, double barrier method of condom and spermicidal) during the treatment period and for at least 12 months after the last dose of study drug; * FT3,FT4 and TSH is normal; * Must have read, understood, and provided written informed consent voluntarily. Willing to adhere to the study visit schedule and the prohibitions and restrictions specified in this protocol. Exclusion Criteria: * Prior treatment with anti-PD-1/PD-L1/PD-L2 antibody; * Hypersensitivity to recombinant humanized anti-PD-1 monoclonal mAb or its components; * Skin melanoma, ocular melanoma, original unknown melanoma; * The primary lesion was incomplete; * The examination suggests that the t…